Skip to main content

FDA Approvals

Imbruvica (Ibrutinib) plus Gazyva (Obinutuzumab) First Chemotherapy-Free Combination Approved as First-Line Treatment for Patients with CLL or SLL

Lilly Ostrovsky

Lilly Ostrovsky

Mavenclad (Cladribine) First Short-Course Oral Therapy Approved for Relapsing-Remitting Multiple Sclerosis and Active Secondary Progressive Disease

Lilly Ostrovsky

Lilly Ostrovsky

Skyrizi (Risankizumab-rzaa) a New Treatment Option Approved by the FDA for Patients with Moderate-to-Severe Plaque Psoriasis

Loretta Fala

Balversa (Erdafitinib), First-in-Class FGFR Kinase Inhibitor, Approved for Patients with Metastatic Urothelial Carcinoma and FGFR Mutations

Loretta Fala

Spravato (Esketamine) Nasal Spray First NMDA Receptor Antagonist Approved by the FDA for Adults with Treatment-Resistant Depression

Loretta Fala

Cablivi (Caplacizumab-yhdp): First Targeted, Nanobody-Based Therapy Approved for Adults with Acquired Thrombotic Thrombocytopenic Purpura

Loretta Fala

FDA Approvals, Biosimilars, Dermatology

Tremfya (Guselkumab), a Novel One-Press Patient-Controlled Injection, Approved for Moderate-to-Severe Plaque Psoriasis

Loretta Fala

Doptelet (Avatrombopag) Receives FDA Approval for the Treatment of Patients with Chronic Immune Thrombocytopenia

Loretta Fala

Zulresso (Brexanolone) First Drug Approved by the FDA Specifically for Postpartum Depression in Adults

Loretta Fala

FDA Oncology Update

Page 21 of 53
Results 201 - 210 of 524